Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Arcutis Biotherapeutics (ARQT) Ownership - Who Owns Arcutis Biotherapeutics?
615 Followers
Arcutis Biotherapeutics (ARQT) Ownership Overview
23.14% Insiders
23.38% Mutual Funds
18.23% Other Institutional Investors
35.25% Public Companies and Individual Investors
The ownership structure of Arcutis Biotherapeutics (ARQT) stock is a mix of institutional, retail and individual investors. Approximately 41.62% of the company’s stock is owned by Institutional Investors, 23.14% is owned by Insiders and 35.25% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Mar 06, 2024 | Patrick Heron Director | Bought | $199994 |
| Jan 03, 2024 | Patrick Burnett Reporting Person's Title: Svp, Chief Medical Officer | Sold | $4691 |
| Dec 01, 2023 | Todd Franklin Watanabe Reporting Person's Title: President And Ceo,director | Bought | $100002 |
| Nov 21, 2023 | Masaru Matsuda Reporting Person's Title: Svp And Gc | Sold | $3645 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $201606 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,829,207 | Institution | 5.94% | 57,843,383 | |
| 4,878,752 | Institution | 4.24% | 41,323,029 | |
| 4,054,419 | Institution | 3.53% | 34,340,929 | |
| 3,725,459 | Institution | 3.24% | 31,554,638 | |
| 3,553,315 | Institution | 3.09% | 30,096,578 | |
| 3,389,514 | Institution | 2.95% | 28,709,184 | |
| 2,745,942 | Institution | 2.39% | 23,258,129 | |
| 1,897,852 | Institution | 1.65% | 16,074,806 | |
| 1,766,984 | Institution | 1.54% | 14,966,354 | |
| 1,439,616 | Institution | 1.25% | 12,193,548 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,054,419 | Institution | 3.53% | 34,340,929 | |
| 3,725,459 | Institution | 3.24% | 31,554,638 | |
| 3,389,514 | Institution | 2.95% | 28,709,184 | |
| 1,897,852 | Institution | 1.65% | 16,074,806 | |
| 1,766,984 | Institution | 1.54% | 14,966,354 | |
| 1,439,616 | Institution | 1.25% | 12,193,548 | |
| 1,102,287 | Institution | 0.96% | 9,336,371 | |
| 850,883 | Institution | 0.74% | 7,206,979 | |
| 844,488 | Institution | 0.73% | 7,152,813 | |
| 799,932 | Institution | 0.70% | 6,775,424 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 6,733,514 | Institution | 5.86% | 58,850,912 | |
| 3,005,949 | Institution | 2.61% | 29,788,955 | |
| 1,876,545 | Institution | 1.63% | 16,401,003 | |
| 1,502,917 | Institution | 1.31% | 14,893,907 | |
| 1,385,268 | Institution | 1.20% | 11,633,907 | |
| 770,162 | Institution | 0.67% | 6,731,216 | |
| 671,493 | Institution | 0.58% | 5,868,849 | |
| 494,474 | Institution | 0.43% | 4,321,703 | |
| 443,042 | Institution | 0.39% | 4,186,747 | |
| 443,042 | Institution | 0.39% | 4,186,747 |
FAQ
Who Owns Arcutis Biotherapeutics (ARQT)?
According to the latest TipRanks data, approximately 18.23% of the company's stock is held by institutional investors, 23.14% is held by insiders, and 35.25% is held by retail investors.
What percentage of Arcutis Biotherapeutics (ARQT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 18.23% of Arcutis Biotherapeutics (ARQT) stock is held by institutional investors.
What percentage of Arcutis Biotherapeutics (ARQT) stock is held by retail investors?
According to the latest TipRanks data, approximately 35.25% of Arcutis Biotherapeutics (ARQT) stock is held by retail investors.
Who owns the most shares of Arcutis Biotherapeutics (ARQT)?
SPDR owns the most shares of Arcutis Biotherapeutics (ARQT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.